Classifica tra le azioni
#14028
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to... Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Prezzo delle azioni
$14.86
Ultima sincronizzazione: 2026-08-31
Capitalizzazione di mercato
$442.29M
Variazione (1 giorno)
-1.13%
Variazione (1 anno)
769.01%
Scambia Q32 Bio Inc. (QTTB)
Ricavi di Q32 Bio Inc. (QTTB)
Ricavi nel Sep 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Q32 Bio Inc., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Q32 Bio Inc. da 2026 a 2026
Ricavi alla fine di ogni anno
| Anno |
Ricavi |
Cambia |
|
Non abbastanza dati per le date fornite. |
Ricavi di aziende simili o concorrenti
| Azienda |
Ricavi |
Differenza nei ricavi |
Il paese |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
$15.74B |
-
|
AU
|
|
|
$2.23B |
-
|
US
|
|
|
- |
-
|
CH
|
